- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus meets with FDA on EchoGen
It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administration’s concerns about the agent’s new drug application (NDA). Sonus
It could be as long as 10 months before Sonus Pharmaceuticals gets its EchoGen ultrasound contrast agent on the market, as it moves to comply with the Food and Drug Administrations concerns about the agents new drug application (NDA). Sonus of Bothell, WA, met with the FDA on April 27 to discuss the NDA after receiving a not-approvable letter for EchoGen in February (SCAN 3/18/98).
Sonus reported that it plans to submit an amendment to EchoGens NDA in the next two to four months to respond to the FDAs concerns regarding the manufacturing processes for EchoGen, including chemistry and analytical methods validation, as well as the companys analysis of animal and clinical data in the application. Once Sonus submits the amendment, the FDA could take up to six months to review it before rendering a decision.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
